- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Fast Growing Stocks With High Insider Ownership
U.S. Pharmaceuticals & Biotech Fast Growing Stocks With High Insider Ownership
Results
23
Companies with strong growth potential, backed by optimistic outlooks both from analysts and management.
23 companies
OS Therapies
Market Cap: US$62.4m
A clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
OSTX
US$1.87
7D
-4.6%
1Y
-29.4%
Abeona Therapeutics
Market Cap: US$246.6m
A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
ABEO
US$4.78
7D
-13.7%
1Y
-20.9%
Corcept Therapeutics
Market Cap: US$7.7b
Engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
CORT
US$74.17
7D
2.2%
1Y
48.2%
Eton Pharmaceuticals
Market Cap: US$483.0m
A pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
ETON
US$18.01
7D
-2.5%
1Y
115.7%
Grace Therapeutics
Market Cap: US$43.6m
Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
GRCE
US$3.11
7D
-1.3%
1Y
-0.8%
Biofrontera
Market Cap: US$11.7m
A biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
BFRI
US$1.10
7D
7.3%
1Y
10.0%
Precigen
Market Cap: US$1.2b
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
PGEN
US$4.16
7D
-3.3%
1Y
411.8%
TriSalus Life Sciences
Market Cap: US$236.4m
Engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers.
TLSI
US$4.74
7D
-5.6%
1Y
19.1%
BioRestorative Therapies
Market Cap: US$13.3m
Develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells.
BRTX
US$1.50
7D
-5.7%
1Y
0%
Krystal Biotech
Market Cap: US$5.7b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
KRYS
US$197.85
7D
4.2%
1Y
15.8%
Liquidia
Market Cap: US$2.1b
A biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
LQDA
US$25.22
7D
10.8%
1Y
141.1%
Clene
Market Cap: US$125.9m
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
CLNN
US$11.98
7D
40.8%
1Y
111.3%
Journey Medical
Market Cap: US$213.6m
Focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
DERM
US$8.52
7D
6.2%
1Y
60.2%
Fennec Pharmaceuticals
Market Cap: US$228.2m
Operates as a commercial stage biopharmaceutical company in the United States.
FENC
US$8.13
7D
-7.8%
1Y
74.8%
ImmunityBio
Market Cap: US$2.4b
A commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases.
IBRX
US$2.26
7D
-15.0%
1Y
-56.5%
Protalix BioTherapeutics
Market Cap: US$189.0m
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
PLX
US$2.39
7D
0.4%
1Y
86.7%
Harrow
Market Cap: US$1.3b
An eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.
HROW
US$35.96
7D
-5.7%
1Y
-21.5%
Dyadic International
Market Cap: US$40.9m
A biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally.
DYAI
US$1.08
7D
-8.5%
1Y
2.9%
Aprea Therapeutics
Market Cap: US$8.2m
A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.
APRE
US$1.40
7D
4.5%
1Y
-64.8%
Celcuity
Market Cap: US$3.3b
A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
CELC
US$75.19
7D
-3.0%
1Y
389.5%
Niagen Bioscience
Market Cap: US$602.6m
Operates as a bioscience company engages in developing healthy aging products.
NAGE
US$7.23
7D
-4.9%
1Y
26.0%
Amneal Pharmaceuticals
Market Cap: US$3.4b
A global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
AMRX
US$11.20
7D
9.2%
1Y
33.1%
Organogenesis Holdings
Market Cap: US$539.1m
A regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States.
ORGO
US$4.00
7D
-6.5%
1Y
33.8%